Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 20

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study

Duivon, Mylène, Lequesne, Justine, Di Meglio, Antonio, Pradon, Caroline, Vaz-Luis, Ines, Martin, Anne-Laure, Everhard, Sibille, Broutin, Sophie, Rigal, Olivier, Bousrih, Chayma, Lévy, Christelle, Lerebours, Florence, Lange, Marie, Joly, Florence·2024·Breast Cancer Research
DOI 10.1186/s13058-024-01850-5
Open this paper in CoChat — free account

Abstract

Background: Inflammation could be related to cancer-related cognitive impairment (CRCI) and might be used as a predictive marker of long-term CRCI. We evaluated associations between inflammatory markers assessed at diagnosis of breast cancer and CRCI two years afterwards. Methods: Newly diagnosed stage I-III patients with breast cancer from the French CANTO-Cog (Cognitive sub-study of CANTO, NCT01993498) were included at diagnosis (baseline). Serum inflammatory markers (IL-2, IL-4, IL-6, IL-8, IL-10, TNFα, CRP) were assessed at baseline. Outcomes at year 2 post-baseline included overall cognitive impairment (≥ 2 impaired domains) and the following domains: episodic memory, working memory, attention, processing speed, and executive functions. Multivariable logistic regression models evaluated associations between markers and outcomes, controlling for age, education, and baseline cognitive impairment. Results: Among 200 patients, the mean age was 54 ± 11 years, with 127 (64%) receiving chemotherapy. Fifty-three (27%) patients had overall cognitive impairment at both timepoints. Overall cognitive impairment at year 2 was associated with high (> 3 mg/L) baseline CRP (OR = 2.84, 95%CI: 1.06–7.64, p = 0.037). In addition, associations were found between high CRP and processing speed impairment (OR = 2.47, 95%CI:1.05–5.87, p = 0.039), and between high IL-6 and episodic memory impairment (OR = 5.50, 95%CI:1.43–36.6, p = 0.010). Conclusions: In this cohort, high levels of CRP and IL-6 assessed at diagnosis were associated with overall CRCI, processing speed and episodic memory impairments two years later. These findings suggest a potential inflammatory basis for long-term CRCI. CRP may represent an easily measurable marker in clinical settings and be potentially used to screen patients at greater risk of persistent CRCI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13058-024-01850-5

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 53

  1. Lange M, Licaj I, Clarisse B, Humbert X, Grellard JM, Tron L, et al. Cognitive complaints in cancer survivors and expectations for support: results from a web–based survey. Cancer Med. 2019;8(5):2654–63. · DOI
  2. Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019;30(12):1925–40. · DOI · Paper page
  3. Janelsins MC, Heckler CE, Peppone LJ, Ahles TA, Mohile SG, Mustian KM, et al. Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study. J Clin Oncol. 2018;36(32):3231–9. · DOI · Paper page
  4. Lange M, Hardy-Léger I, Licaj I, Pistilli B, Rigal O, Le Fel J, et al. Cognitive impairment in patients with breast cancer before surgery: results from a CANTO cohort subgroup. Cancer Epidemiol Biomark Prev. 2020;29(9):1759–66. · DOI
  5. Koppelmans V, Breteler MMB, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30(10):1080–6. · DOI · Paper page
  6. Lange M, Arbogast SL, Hardy-Léger I, Rigal O, Le Fel J, Pistilli B, et al. Cognitive change in breast cancer patients up to 2 years after diagnosis. JNCI J Nat Cancer Inst. 2022;115:322–31. · doi:10.1093/jnci/djac240
  7. Oppegaard KR, Armstrong TS, Anguera JA, Kober KM, Kelly DL, Laister RC, et al. Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: a scoping review. Crit Rev Oncol Hematol déc. 2022;180:103822. · DOI
  8. Schroyen G, Vissers J, Smeets A, Gillebert CR, Lemiere J, Sunaert S, et al. Blood and neuroimaging biomarkers of cognitive sequelae in breast cancer patients throughout chemotherapy: a systematic review. Transl Oncol. 2022;16:101297. · DOI
  9. Van Der Willik KD, Koppelmans V, Hauptmann M, Compter A, Ikram MA, Schagen SB. Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: A cohort study. Breast Cancer Res. 2018;20(1):1–10. · DOI
  10. Mandelblatt JS, Small BJ, Zhou X, Nakamura ZM, Cohen HJ, Ahles TA, et al. Plasma levels of interleukin-6 mediate neurocognitive performance in older breast cancer survivors: the thinking and living with cancer study. Cancer. 2023;129(15):2409–21. · DOI · Paper page
  11. Janelsins MC, Lei L, Netherby-Winslow C, Kleckner AS, Kerns S, Gilmore N, et al. Relationships between cytokines and cognitive function from pre- to post-chemotherapy in patients with breast cancer. J Neuroimmunol. 2022;362:577769. · DOI · Paper page
  12. Ren X, St. Clair DK, Butterfield DA. Dysregulation of cytokine mediated chemotherapy induced cognitive impairment. Pharmacol Res. 2017;117:267–73. · DOI
  13. Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, et al. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study†. Annal Oncol. 2015;26(7):1446–51. · DOI · Paper page
  14. Toh YL, Wang C, Ho HK, Chan A. Distinct cytokine profiles across trajectories of self-perceived cognitive impairment among early-stage breast cancer survivors. J Neuroimmunol. 2020;342:577196. · DOI
  15. Belcher EK, Culakova E, Gilmore NJ, Hardy SJ, Kleckner AS, Kleckner IR, et al. Inflammation, attention, and processing speed in patients with breast cancer before and after chemotherapy. JNCI J Nat Cancer Inst. 2022;114(5):712–21. · DOI
  16. Carroll JE, Nakamura ZM, Small BJ, Zhou X, Cohen HJ, Ahles TA, et al. Elevated C-reactive protein and subsequent patient-reported cognitive problems in older breast cancer survivors: the thinking and living with cancer study. J Clin Oncol. 2022;41:295–306. · DOI · Paper page
  17. Vaz-Luis I, Cottu P, Mesleard C, Martin AL, Dumas A, Dauchy S, et al. UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open. 2019;4(5):e000562. · DOI
  18. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98. · DOI · Paper page
  19. Brickenkamp R, Zillmer E. The d2 Test of Attention. Seattle, WA: Hogrefe and Huber Publishers; 1998.
  20. Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y. Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg. 1990;90(4):207–17.
  21. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Motor Skills. 1958;8(3):271–6. · DOI · Paper page
  22. Stroop J. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643. · DOI · Paper page
  23. Wefel JS, Vardy J, Ahles T, Schagen SB. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–8. · DOI · Paper page
  24. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70. · DOI · Paper page
  25. Lyon DE, Cohen R, Chen H, Kelly DL, McCain NL, Starkweather A, et al. Relationship of systemic cytokine concentrations to cognitive function over two years in women with early stage breast cancer. J Neuroimmunol. 2016;301:74–82. · DOI
  26. Kesler SR, Janelsins M, Koovakkattu D, Palesh O, Mustian K, Morrow G, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30(SUPPL.):S109–16. · DOI · Paper page
  27. Henneghan AM, Palesh O, Harrison M, Kesler SR. Identifying cytokine predictors of cognitive functioning in breast cancer survivors up to 10 years post chemotherapy using machine learning. J Neuroimmunol. 2018;320:38–47. · DOI
  28. Shibayama O, Yoshiuchi K, Inagaki M, Matsuoka Y, Yoshikawa E, Sugawara Y, et al. Long-term influence of adjuvant breast radiotherapy on cognitive function in breast cancer patients treated with conservation therapy. Int J Clin Oncol. 2019;24(1):68–77. · DOI
  29. Vardy JL, Stouten-Kemperman MM, Pond G, Booth CM, Rourke SB, Dhillon HM, et al. A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging Behav. 2017;13(1):15–26. · DOI
  30. Henneghan A, Wright ML, Bourne G, Sales AC. A cross-sectional exploration of cytokine-symptom networks in breast cancer survivors using network analysis. Can J Nurs Res. 2021;55(3):303–15. · DOI
  31. Shibayama O, Yoshiuchi K, Inagaki M, Matsuoka Y, Yoshikawa E, Sugawara Y, et al. Association between adjuvant regional radiotherapy and cognitive function in breast cancer patients treated with conservation therapy. Cancer Med. 2014;3(3):702–9. · DOI
  32. Janelsins MC, Mustian KM, Palesh OG, Mohile SG, Peppone LJ, Sprod LK, et al. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer avr. 2012;20(4):831–9. · DOI
  33. Amidi A, Agerbæk M, Wu LM, Pedersen AD, Mehlsen M, Clausen CR, et al. Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. Brain Imaging Behav. 2017;11(3):769–83. · DOI
  34. Henry NL, Pchejetski D, A’Hern R, Nguyen AT, Charles P, Waxman J, et al. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study. Br J Cancer. 2010;103(3):291–6. · DOI
  35. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 2005;4(6):371–80. · DOI · Paper page
  36. Hsu PF, Pan WH, Yip BS, Chen RCY, Cheng HM, Chuang SY. C-reactive protein predicts incidence of dementia in an elderly Asian community cohort. J Am Med Dir Assoc. 2017;18(3):277.e7-277.e11. · DOI
  37. Yang J, Fan C, Pan L, Xie M, He Q, Li D, et al. C-reactive protein plays a marginal role in cognitive decline: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2015;30(2):156–65. · DOI
  38. Starkweather A, Kelly DL, Thacker L, Wright ML, Jackson-Cook CK, Lyon DE. Relationships among psychoneurological symptoms and levels of C-reactive protein over 2 years in women with early-stage breast cancer. Support Care Cancer. 2017;25(1):167–76. · DOI
  39. Braida D, Sacerdote P, Panerai AE, Bianchi M, Aloisi AM, Iosuè S, et al. Cognitive function in young and adult IL (interleukin)-6 deficient mice. Behav Brain Res. 2004;153(2):423–9. · DOI · Paper page
  40. Lykhmus O, Kalashnyk O, Koval L, Voytenko L, Uspenska K, Komisarenko S, et al. Mesenchymal stem cells or interleukin-6 improve episodic memory of mice lacking α7 nicotinic acetylcholine receptors. Neuroscience. 2019;413:31–44. · DOI
  41. Harrell ER, Bui C, Newman SD. Alzheimer’s Disease Neuroimaging Initiative (ADNI). A mixed-effects model of associations between interleukin-6 and hippocampal volume. J Gerontol Ser A. 2022;77(4):683–8. · DOI
  42. Lyra e Silva NM, Gonçalves RA, Pascoal TA, Lima-Filho RAS, de Resende EPF, Vieira ELM, et al. Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer’s disease. Transl Psychiatry. 2021;11(1):1–15. · DOI · Paper page
  43. Zhao J, Zuo H, Ding K, Zhang X, Bi Z, Cheng H. Changes in plasma IL-1β, TNF-α and IL-4 levels are involved in chemotherapy-related cognitive impairment in early-stage breast cancer patients. Am J Trans Res. 2020;12(6):3046.
  44. Williams AM, Shah R, Shayne M, Huston A, Krebs M, Murray N, et al. Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy. J Neuroimmunol. 2018;314:17–23. · DOI
  45. Pertl MM, Hevey D, Boyle NT, Hughes MM, Collier S, O’Dwyer AM, et al. C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy. Brain Behav Immun. 2013;1(34):108–19. · DOI
  46. Bennett B, Goldstein D, Lloyd A, Davenport T, Hickie I. Fatigue and psychological distress–exploring the relationship in women treated for breast cancer. Eur J Cancer. 2004;40(11):1689–95. · DOI
  47. Bower JE. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol. 2008;26(5):768–77. · DOI · Paper page
  48. Pang L, Li W, Yao S, Jing Y, Yin X, Cheng H. Psychological distress is involved in CRCI in breast cancer survivors via mediating cytokine levels. Cancer Med mai. 2023;12(10):11806–15. · DOI
  49. Ma C, Lin M, Gao J, Xu S, Huang L, Zhu J, et al. The impact of physical activity on blood inflammatory cytokines and neuroprotective factors in individuals with mild cognitive impairment: a systematic review and meta-analysis of randomized-controlled trials. Aging Clin Exp Res. 2022;34(7):1471–84. · DOI
  50. Kiecolt-Glaser JK, Bennett JM, Andridge R, Peng J, Shapiro CL, Malarkey WB, et al. Yoga’s Impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2014;32(10):1040–9. · DOI · Paper page
  51. Salerno EA, Culakova E, Kleckner AS, Heckler CE, Lin PJ, Matthews CE, et al. Physical activity patterns and relationships with cognitive function in patients with breast cancer before, during, and after chemotherapy in a prospective, nationwide study. J Clin Oncol. 2021;39(29):3283. · DOI
  52. Zimmer P, Baumann FT, Oberste M, Wright P, Garthe A, Schenk A, et al. Effects of exercise interventions and physical activity behavior on cancer related cognitive impairments: a systematic review. BioMed Res Int. 2016;2016:e1820954. · DOI · Paper page
  53. Duivon M, Lange M, Binarelli G, Lefel J, Hardy-Léger I, Kiasuwa-Mbengi R, et al. Improve the management of cancer-related cognitive impairment in clinical settings: a European Delphi study. J Cancer Surviv. 2023;27:2077.

Metadata

Authors
Duivon, M., Lequesne, J., Di Meglio, A., Pradon, C., Vaz-Luis, I., Martin, A.-L., Everhard, S., Broutin, S., Rigal, O., Bousrih, C., Lévy, C., Lerebours, F., Lange, M., & Joly, F.
Venue
Breast Cancer Research
Publisher
Springer Science and Business Media LLC
Published
2024-06-05
Volume
26
Issue
1
ISSN
1465-542X
DOI
10.1186/s13058-024-01850-5
Cited by
20
References
5
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study. https://app.cochat.ai/papers/10.1186/s13058-024-01850-5
The paper
Duivon, M., Lequesne, J., Di Meglio, A., Pradon, C., Vaz-Luis, I., Martin, A.-L., Everhard, S., Broutin, S., Rigal, O., Bousrih, C., Lévy, C., Lerebours, F., Lange, M., & Joly, F. (2024). Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study. Breast Cancer Research. https://doi.org/10.1186/s13058-024-01850-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.